Page 49 - Ohnson Johnson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The European Union's drug regulator said on Wednesday it is reviewing the death of a woman in Belgium who suffered a blood clot and low platelets after receiving Johnson & Johnson's COVID-19 vaccine. The European Medicines Agency (EMA) said it has asked the U.S. drugmaker to carry out a series of additional studies to help assess a possible link between the shot and a known rare but serious clotting condition called thrombosis with thrombocytopenia syndrome (TTS). It said it is reviewing the case in Belgium along with other reports of blood clots with the Belgian and Slovenian...

  >>  Reuters Published: 25 May 2021 07:20 PM BdST Updated: 25 May 2021 07:20 PM BdST A woman sits as she waits at a COVID-19 vaccination centre, amid the coronavirus disease outbreak, in Ronquieres, Belgium March 15, 2021. REUTERS The European Union expects to have received more than a billion doses of COVID-19 vaccines by the end of September from four drugmakers, a document presented to EU leaders on Tuesday shows. "); } The document, seen by Reuters and prepared ...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today follow-up data from the MonumenTAL-1 Phase 1 first-in-human dose-escalation study of the investigational product talquetamab, the only off-the-shelf T-cell redirecting bispecific antibody in clinical development to target both GPRC5D, a novel multiple myeloma target, and CD3 on T-cells (NCT03399799).1,2,3 With a median follow-up of more than six months, updated results in 30 patients with relapsed or refractory multiple myeloma treated with talquetamab by subcutaneous (SC) administration at the recommended Phase 2 d...

The CEO Roundtable on Cancer has elected Scott White, Company Group Chairman for North America at the Janssen Pharmaceutical Companies of Johnson & Johnson, to its Board of Directors.

Major US retailers and resorts are lifting indoor mask mandates for vaccinated people after updated CDC advice